Guidelines for Pediatric Unrelated Cord Blood Transplantation-Unique Considerations.

{"article_title":"Guidelines for Pediatric Unrelated Cord Blood Transplantation-Unique Considerations.","author":"Dahlberg A, Kurtzberg J, Boelens J, Martinez C, Carpenter P, Tewari P","journal_title":"Transplantation and cellular therapy","issn":"2666-6367","isbn":"","publication_date":"2021-12-01","volume":"27","issue":"12","first_page":"968","page_count":"","accession_number":"34571212","doi":"10.1016\/j.jtct.2021.09.013","publisher":"Elsevier Inc","doctype":"Practice Guideline","subjects":"Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Child; Fetal Blood; Humans; Unrelated Donors","interest_area":["Pediatric Medicine"],"abstract":"Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA-matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic graft-versus-host disease (GVHD). In addition, CB has unique properties that make it the stem cell source of choice for some nonmalignant conditions such as metabolic disorders. This review provides evidence-based and experience-based pediatric-specific guidelines for CBT including considerations for infectious disease management, CB unit selection and infusion, conditioning regimen selection, and GVHD management. In addition, it covers unique bedside considerations for pediatric patients and CB banking. In concert with the other topic specific CB guidelines previously published in this series, it provides a comprehensive overview of the clinical management of pediatric CBT. Copyright \u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34571212","isPdfLink":false,"isSAML":true,"an":"34571212","number_other":"","type_pub":"","issn_electronic":"2666-6367","languages":"English","language":"eng","date_entry":"Date Created: 20210927 Date Completed: 20220125 Latest Revision: 20220125","date_update":"20240105","titleSource":"Transplantation and cellular therapy [Transplant Cell Ther] 2021 Dec; Vol. 27 (12), pp. 968-972. Date of Electronic Publication: 2021 Sep 24.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2021-12-01","description":"Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA-matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic graft-versus-host disease (GVHD). In addition, CB has unique properties that make it the stem cell source of choice for some nonmalignant conditions such as metabolic disorders. This review provides evidence-based and experience-based pediatric-specific guidelines for CBT including considerations for infectious disease management, CB unit selection and infusion, conditioning regimen selection, and GVHD management. In addition, it covers unique bedside considerations for pediatric patients and CB banking. In concert with the other topic specific CB guidelines previously published in this series, it provides a comprehensive overview of the clinical management of pediatric CBT.<br \/> (Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)","upload_link":"https:\/\/go.openathens.net\/redirector\/shalina.com?url=https:\/\/resolver.ebscohost.com\/openurl?sid=EBSCO:mdl&genre=article&issn=26666367&ISBN=&volume=27&issue=12&date=20211201&spage=968&pages=968-972&title=Transplantation and cellular therapy&atitle=Guidelines%20for%20Pediatric%20Unrelated%20Cord%20Blood%20Transplantation-Unique%20Considerations.&aulast=Dahlberg%20A&id=DOI:10.1016\/j.jtct.2021.09.013&authtype=ip,shib&custid=ns346513&groupid=main&profile=eds","no_of_pages":"","authored_by":"Dahlberg A, Kurtzberg J, Boelens J, Martinez C, Carpenter P, Tewari P"}